Abstract
We use the 2014 market history of two high-returning biotechnology
exchange-traded funds to illustrate how ex post mean-variance analysis should
not be done. Unfortunately, the way it should not be done is the way it
generally is done -- to our knowledge.
Users
Please
log in to take part in the discussion (add own reviews or comments).